Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Suite 2175, Miami, FL 33136, USA.
Lasers Med Sci. 2011 Sep;26(5):641-4. doi: 10.1007/s10103-011-0952-8. Epub 2011 Jul 12.
Basal cell carcinomas (BCC) have a specialized microvasculature system that can be targeted by the 585-nm pulsed dye laser (PDL) utilizing the theory of selective photothermolysis. Seven volunteers with nine well-defined, biopsy-proven BCCs, were treated with the PDL (585-nm wavelength, a single 450-μs pulse, 7-mm spot size, and 9.0 J/cm(2) energy). The lesions, along with a 4-mm border of normal skin were treated. Pain assessment was carried out immediately after the laser treatment. A deep shave biopsy with histological examination occurred 4 weeks after the laser treatment. Pain was assessed on a scale of 0 (no pain) to 10 (worst pain possible). The average patient score was 2.1 (range 1-4). On histology, 5/9 (55.6%) sites demonstrated no evidence of BCC; however, 4/9 (44.4%) sites showed residual BCC. Although the PDL was able to clear over half of the BCCs in this study, there was an unacceptably high persistence rate of 44.4%. The PDL did not achieve the clearance rate that can be attained with current standard BCC treatment modalities. At this time, we do not recommend that a single treatment with the 585-nm PDL can be used as a primary therapy for BCC.
基底细胞癌 (BCC) 具有专门的微血管系统，可以通过利用选择性光热分解理论的 585nm 脉冲染料激光 (PDL) 进行靶向治疗。7 名志愿者的 9 个明确诊断、活检证实的 BCC 接受了 PDL（585nm 波长、单次 450μs 脉冲、7mm 光斑大小和 9.0J/cm² 能量）治疗。病变部位及 4mm 正常皮肤边界均接受治疗。激光治疗后立即进行疼痛评估。激光治疗后 4 周进行深部刮除活检和组织学检查。疼痛评估采用 0（无痛）到 10（可能的最痛）的量表进行。平均患者评分为 2.1（范围 1-4）。组织学上，5/9（55.6%）部位未见 BCC 证据；然而，4/9（44.4%）部位仍有 BCC 残留。尽管 PDL 能够清除本研究中超过一半的 BCC，但仍有 44.4%的不可接受的高残留率。PDL 并未达到目前标准 BCC 治疗方法所能达到的清除率。目前，我们不建议将 585nm PDL 的单次治疗用作 BCC 的主要治疗方法。
